{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Maximo V"],"funding":["Foundation for Science and Technology, Portugal"],"pagination":["505-509"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11489207"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["86(2)"],"pubmed_abstract":["<h4>Purpose</h4>To perform a molecular profiling of the metastases from papillary thyroid carcinomas (PTCs) and poorly differentiated thyroid carcinomas (PDTCs).<h4>Methods</h4>We retrieved and analyzed the molecular and clinical features of 136 metastases from PTCs and 35 metastases from PDTCs subjected to targeted DNA sequencing, from cBioPortal. The clinicopathological data included the number and location of the metastases, and genomic data included mutations, translocations, copy number alterations and fraction of the genome altered (FGA).<h4>Results</h4>Bone metastases from PTCs had a lower frequency of BRAF mutations than the lymph node metastases (LNMs) (43% vs 88%, p < 0.01), and a higher frequency of RBM10 and NRAS mutations than the LNMs (21% vs 3% for both, p < 0.05). The FGA o"],"journal":["Endocrine"],"pubmed_title":["Genomic profiling of lymph node and distant metastases from papillary and poorly differentiated thyroid carcinomas."],"pmcid":["PMC11489207"],"funding_grant_id":["2022.05763.PTDC"],"pubmed_authors":["Sobrinho-Simoes M","Da Cruz Paula A","Maximo V","Soares P","Melo M"],"additional_accession":[]},"is_claimable":false,"name":"Genomic profiling of lymph node and distant metastases from papillary and poorly differentiated thyroid carcinomas.","description":"<h4>Purpose</h4>To perform a molecular profiling of the metastases from papillary thyroid carcinomas (PTCs) and poorly differentiated thyroid carcinomas (PDTCs).<h4>Methods</h4>We retrieved and analyzed the molecular and clinical features of 136 metastases from PTCs and 35 metastases from PDTCs subjected to targeted DNA sequencing, from cBioPortal. The clinicopathological data included the number and location of the metastases, and genomic data included mutations, translocations, copy number alterations and fraction of the genome altered (FGA).<h4>Results</h4>Bone metastases from PTCs had a lower frequency of BRAF mutations than the lymph node metastases (LNMs) (43% vs 88%, p < 0.01), and a higher frequency of RBM10 and NRAS mutations than the LNMs (21% vs 3% for both, p < 0.05). The FGA o","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2025-04-03T23:18:32.61Z","creation":"2025-04-03T23:18:32.61Z"},"accession":"S-EPMC11489207","cross_references":{"pubmed":["39030377"],"doi":["10.1007/s12020-024-03968-0"]}}